Cargando…

Myrtenal and β-caryophyllene oxide screened from Liquidambaris Fructus suppress NLRP3 inflammasome components in rheumatoid arthritis

BACKGROUND: Liquidambaris Fructus (LF) is the infructescence of Liquidambar formosana. In Traditional Chinese Medicine, LF has been used to treat joint pain, a common symptom of arthritis and rheumatism; however, a lack of pharmacological evidence has limited its applications in modern clinics. Ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wen-xuan, Qian, Ping, Guo, Yi-tong, Gu, Li, Jurat, Jessore, Bai, Yang, Zhang, Dong-fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480017/
https://www.ncbi.nlm.nih.gov/pubmed/34583676
http://dx.doi.org/10.1186/s12906-021-03410-2
_version_ 1784576384974192640
author Li, Wen-xuan
Qian, Ping
Guo, Yi-tong
Gu, Li
Jurat, Jessore
Bai, Yang
Zhang, Dong-fang
author_facet Li, Wen-xuan
Qian, Ping
Guo, Yi-tong
Gu, Li
Jurat, Jessore
Bai, Yang
Zhang, Dong-fang
author_sort Li, Wen-xuan
collection PubMed
description BACKGROUND: Liquidambaris Fructus (LF) is the infructescence of Liquidambar formosana. In Traditional Chinese Medicine, LF has been used to treat joint pain, a common symptom of arthritis and rheumatism; however, a lack of pharmacological evidence has limited its applications in modern clinics. Therefore, this study aims to explore the protective effect of LF on rheumatoid arthritis (RA) and to identify its active ingredients. METHODS: Rats with adjuvant-induced arthritis (AIA) were divided into 4 groups and administered petroleum ether extract of LF (PEL), ethyl acetate extract of LF (EEL), water extract of LF (WEL), or piroxicam (PIR) respectively for 3 weeks. Two additional groups were used as normal control (NC) and model control (MC) and administered distilled water as a placebo. The clinical scores for arthritis, bone surface, synovial inflammation and cartilage erosion were used to evaluate the therapeutic efficacy of each treatment. The serum IL-1β and TNF-α level and the expression of NLRP3, IL-1β and caspase-1 p20 in the synovial tissue of AIA rats were evaluated by ELISA and Western blot. The active ingredients of LF were investigated using network pharmacology and molecular docking methods, and their inhibition of NLRP3 inflammasome activation was verified in the human rheumatoid arthritis fibroblast-like synovial cells (RA-FLS) model. RESULTS: PEL could alleviate paw swelling, bone and joint destruction, synovial inflammation and cartilage erosion in the AIA rats, with significantly superior efficacy to that of EEL and WEL. PEL reduced IL-1β and TNF-α serum levels, and attenuated the upregulation of NLRP3, IL-1β and caspase-1 p20 expression in the synovial tissue of AIA rats. Network pharmacology and molecular docking results indicated that myrtenal and β-caryophyllene oxide were the main two active ingredients of PEL, and these two compounds showed significant inhibition on TNF-α, NLRP3, IL-1β and caspase-1 p20 expression in RA-FLS. CONCLUSIONS: Myrtenal and β-caryophyllene oxide screened from PEL could suppress the activation of NLRP3 inflammasome, thereby alleviating RA symptoms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12906-021-03410-2.
format Online
Article
Text
id pubmed-8480017
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84800172021-09-30 Myrtenal and β-caryophyllene oxide screened from Liquidambaris Fructus suppress NLRP3 inflammasome components in rheumatoid arthritis Li, Wen-xuan Qian, Ping Guo, Yi-tong Gu, Li Jurat, Jessore Bai, Yang Zhang, Dong-fang BMC Complement Med Ther Research BACKGROUND: Liquidambaris Fructus (LF) is the infructescence of Liquidambar formosana. In Traditional Chinese Medicine, LF has been used to treat joint pain, a common symptom of arthritis and rheumatism; however, a lack of pharmacological evidence has limited its applications in modern clinics. Therefore, this study aims to explore the protective effect of LF on rheumatoid arthritis (RA) and to identify its active ingredients. METHODS: Rats with adjuvant-induced arthritis (AIA) were divided into 4 groups and administered petroleum ether extract of LF (PEL), ethyl acetate extract of LF (EEL), water extract of LF (WEL), or piroxicam (PIR) respectively for 3 weeks. Two additional groups were used as normal control (NC) and model control (MC) and administered distilled water as a placebo. The clinical scores for arthritis, bone surface, synovial inflammation and cartilage erosion were used to evaluate the therapeutic efficacy of each treatment. The serum IL-1β and TNF-α level and the expression of NLRP3, IL-1β and caspase-1 p20 in the synovial tissue of AIA rats were evaluated by ELISA and Western blot. The active ingredients of LF were investigated using network pharmacology and molecular docking methods, and their inhibition of NLRP3 inflammasome activation was verified in the human rheumatoid arthritis fibroblast-like synovial cells (RA-FLS) model. RESULTS: PEL could alleviate paw swelling, bone and joint destruction, synovial inflammation and cartilage erosion in the AIA rats, with significantly superior efficacy to that of EEL and WEL. PEL reduced IL-1β and TNF-α serum levels, and attenuated the upregulation of NLRP3, IL-1β and caspase-1 p20 expression in the synovial tissue of AIA rats. Network pharmacology and molecular docking results indicated that myrtenal and β-caryophyllene oxide were the main two active ingredients of PEL, and these two compounds showed significant inhibition on TNF-α, NLRP3, IL-1β and caspase-1 p20 expression in RA-FLS. CONCLUSIONS: Myrtenal and β-caryophyllene oxide screened from PEL could suppress the activation of NLRP3 inflammasome, thereby alleviating RA symptoms. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12906-021-03410-2. BioMed Central 2021-09-28 /pmc/articles/PMC8480017/ /pubmed/34583676 http://dx.doi.org/10.1186/s12906-021-03410-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Wen-xuan
Qian, Ping
Guo, Yi-tong
Gu, Li
Jurat, Jessore
Bai, Yang
Zhang, Dong-fang
Myrtenal and β-caryophyllene oxide screened from Liquidambaris Fructus suppress NLRP3 inflammasome components in rheumatoid arthritis
title Myrtenal and β-caryophyllene oxide screened from Liquidambaris Fructus suppress NLRP3 inflammasome components in rheumatoid arthritis
title_full Myrtenal and β-caryophyllene oxide screened from Liquidambaris Fructus suppress NLRP3 inflammasome components in rheumatoid arthritis
title_fullStr Myrtenal and β-caryophyllene oxide screened from Liquidambaris Fructus suppress NLRP3 inflammasome components in rheumatoid arthritis
title_full_unstemmed Myrtenal and β-caryophyllene oxide screened from Liquidambaris Fructus suppress NLRP3 inflammasome components in rheumatoid arthritis
title_short Myrtenal and β-caryophyllene oxide screened from Liquidambaris Fructus suppress NLRP3 inflammasome components in rheumatoid arthritis
title_sort myrtenal and β-caryophyllene oxide screened from liquidambaris fructus suppress nlrp3 inflammasome components in rheumatoid arthritis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480017/
https://www.ncbi.nlm.nih.gov/pubmed/34583676
http://dx.doi.org/10.1186/s12906-021-03410-2
work_keys_str_mv AT liwenxuan myrtenalandbcaryophylleneoxidescreenedfromliquidambarisfructussuppressnlrp3inflammasomecomponentsinrheumatoidarthritis
AT qianping myrtenalandbcaryophylleneoxidescreenedfromliquidambarisfructussuppressnlrp3inflammasomecomponentsinrheumatoidarthritis
AT guoyitong myrtenalandbcaryophylleneoxidescreenedfromliquidambarisfructussuppressnlrp3inflammasomecomponentsinrheumatoidarthritis
AT guli myrtenalandbcaryophylleneoxidescreenedfromliquidambarisfructussuppressnlrp3inflammasomecomponentsinrheumatoidarthritis
AT juratjessore myrtenalandbcaryophylleneoxidescreenedfromliquidambarisfructussuppressnlrp3inflammasomecomponentsinrheumatoidarthritis
AT baiyang myrtenalandbcaryophylleneoxidescreenedfromliquidambarisfructussuppressnlrp3inflammasomecomponentsinrheumatoidarthritis
AT zhangdongfang myrtenalandbcaryophylleneoxidescreenedfromliquidambarisfructussuppressnlrp3inflammasomecomponentsinrheumatoidarthritis